Addex Therapeutics Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Addex Therapeutics Ltd. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Addex Therapeutics Ltd. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Addex Therapeutics has little or no product revenue yet; it used $3m of cash in the twelve months. The diluted share count is up 9.4% on a year earlier, which dilutes existing holders. It passes 5 of our 6 financial-health checks.
Our model value for Addex Therapeutics is under review, so past values are not shown until it is resolved.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Addex Therapeutics Ltd.'s trailing-twelve-month revenue fell 92.1% year on year, with a free-cash-flow margin of -7243.8%.
Current signal Revenue growth decelerating: TTM revenue growth slowed to -92.1% (-17.7pp vs the prior quarter), the 2nd consecutive quarterly slowdown.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for ADXN from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Addex Therapeutics Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.0 ~$0.1–$0.3 | Left out: out of range vs price (0.01x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Addex Therapeutics Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
No analyst estimates are published for Addex Therapeutics Ltd.: too few analysts cover it.
Source: SEC EDGAR filings. Retrieved November 2, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY18 Q4 | $6.2M |
| FY19 Q4 | $2.8M |
| FY20 Q4 | $3.9M |
| FY21 Q4 | $3.2M |
| FY22 Q4 | $1.5M |
| FY23 Q4 | $1.8M |
| FY24 Q4 | $459K |
| FY25 Q4 | $36.2K |
Source: SEC EDGAR filings. Retrieved November 2, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY19 Q4 | -55.0% |
| FY20 Q4 | 38.5% |
| FY21 Q4 | -17.2% |
| FY22 Q4 | -53.3% |
| FY23 Q4 | 20.5% |
| FY24 Q4 | -74.4% |
| FY25 Q4 | -92.1% |
Source: SEC EDGAR filings. Retrieved November 2, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY18 Q4 | -23.6% |
| FY19 Q4 | -528.6% |
| FY20 Q4 | -338.9% |
| FY21 Q4 | -531.7% |
| FY22 Q4 | -741.0% |
| FY23 Q4 | -139.1% |
| FY24 Q4 | -681.8% |
| FY25 Q4 | -9390.8% |
Source: SEC EDGAR filings. Retrieved November 2, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY18 Q4 | 28.8% |
| FY19 Q4 | -344.2% |
| FY20 Q4 | -338.8% |
| FY21 Q4 | -505.3% |
| FY22 Q4 | -1155.6% |
| FY23 Q4 | -495.9% |
| FY24 Q4 | -1330.1% |
| FY25 Q4 | -7243.8% |
| Fiscal year | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 6 | 3 | 4 | 3 | 1 | 2 | 0 | 0 |
| EBITDA | −1 | −14 | −13 | −17 | −11 | −2 | −3 | −3 |
| Operating income | −1 | −15 | −13 | −17 | −11 | −2 | −3 | −3 |
| Net income | −2 | −15 | −14 | −17 | −22 | −12 | 8 | −8 |
| Diluted EPS | — | −$67.63 | −$61.41 | −$59.07 | −$57.85 | −$18.71 | $9.54 | −$8.69 |
| Growth (year on year) | ||||||||
| Revenue | — | −55.0% | +38.5% | −17.2% | −53.3% | +20.5% | −74.4% | −92.1% |
| Net income | — | — | — | — | — | — | — | −201.3% |
| Diluted EPS | — | — | — | — | — | — | — | −191.1% |
| Margins | ||||||||
| EBITDA margin | −23.5% | −516.5% | −328.4% | −519.8% | −740.4% | −138.3% | −634.1% | <−999% |
| Operating margin | −23.6% | −528.6% | −338.9% | −531.7% | −741.0% | −139.1% | −681.8% | <−999% |
| Net margin | −27.2% | −535.0% | −355.9% | −526.4% | <−999% | −654.5% | >999% | <−999% |
| Free-cash-flow margin | 28.8% | −344.2% | −338.8% | −505.3% | <−999% | −495.9% | <−999% | <−999% |
| Cash flow | ||||||||
| Cash from operations | 2 | −10 | −13 | −16 | −17 | −9 | −6 | −3 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 2 | −10 | −13 | −16 | −17 | −9 | −6 | −3 |
| Stock-based pay | 2 | 2 | 1 | 1 | 4 | 2 | 1 | 0 |
| Free cash flow after stock pay | −1 | −11 | −14 | −17 | −21 | −11 | −7 | −3 |
| Balance sheet | ||||||||
| Cash | 32 | 33 | 21 | 22 | 8 | 5 | 4 | 2 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −32 | −33 | −21 | −22 | −8 | −5 | −4 | −2 |
| Diluted shares | — | — | — | — | — | — | — | — |
| Last 12 months unless stated | ADXN | LYEL | AIM | IBIO | LSTA | CLDX | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $36178 | $27000 | $95000 | $100000 | $100000 | $158000 | $55m |
| Revenue growth, last 12 months | −92.1% | −55.0% | −21.5% | −75.0% | −90.7% | −97.3% | 12.2% |
| Revenue growth, 3-year average | — | −91.8% | −17.3% | −62.4% | — | −63.5% | 13.7% |
| Revenue growth, latest quarter | — | −50.0% | 4.0% | −100.0% | −100.0% | −97.0% | 10.2% |
| Gross margin | — | — | −968.5% | 59.9% | 7.7% | — | 82.9% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −191.1% |
| Operating margin, 3-year average | — | <−999% | <−999% | <−999% | <−999% | <−999% | −363.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | — | <−999% | <−999% | <−999% | <−999% | <−999% | −310.0% |
| Stock pay / revenue | 236.3% | >999% | 0.0% | >999% | >999% | >999% | 20.7% |
| Change in share count | 9.4% | — | 49.8% | 13.9% | 5.1% | 4.7% | 8.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| UBS Group AG | $268 | 0K | 97.8% | New |
| Sbi Securities Co., Ltd. | $6 | 0K | 2.2% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Addex Therapeutics Ltd.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
